221 related articles for article (PubMed ID: 16893744)
21. [Cutaneous side effects of EGF-receptor inhibition and their management].
Gutzmer R; Werfel T; Kapp A; Elsner J
Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
[TBL] [Abstract][Full Text] [Related]
22. [Cutaneous side effects of EGF receptor inhibitors].
Nassar D; Soutou B; Aractingi S
Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
[TBL] [Abstract][Full Text] [Related]
23. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
[TBL] [Abstract][Full Text] [Related]
24. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
Dear R; Wilcken N; Shannon J
Aust Fam Physician; 2008; 37(1-2):45-9. PubMed ID: 18239753
[TBL] [Abstract][Full Text] [Related]
25. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition.
Reck M; Gutzmer R
Onkologie; 2010; 33(8-9):470-9. PubMed ID: 20838065
[TBL] [Abstract][Full Text] [Related]
26. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
27. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
Peréz-Soler R; Saltz L
J Clin Oncol; 2005 Aug; 23(22):5235-46. PubMed ID: 16051966
[TBL] [Abstract][Full Text] [Related]
28. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Segaert S; Tabernero J; Chosidow O; Dirschka T; Elsner J; Mancini L; Maughan T; Morere JF; Santoro A; Sobrero A; Van Cutsem E; Layton A
J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
[TBL] [Abstract][Full Text] [Related]
29. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
[TBL] [Abstract][Full Text] [Related]
30. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Bragg J; Pomeranz MK
Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker.
Bianchini D; Jayanth A; Chua YJ; Cunningham D
Clin Colorectal Cancer; 2008 Jan; 7(1):33-43. PubMed ID: 18279575
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Wood LS; Manchen B
Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
[TBL] [Abstract][Full Text] [Related]
34. Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors.
Boucher J; Olson L; Piperdi B
Clin J Oncol Nurs; 2011 Oct; 15(5):501-8. PubMed ID: 21951736
[TBL] [Abstract][Full Text] [Related]
35. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors.
Marshall J
Cancer; 2006 Sep; 107(6):1207-18. PubMed ID: 16909423
[TBL] [Abstract][Full Text] [Related]
36. Targeted therapies: a nursing perspective.
Kay P
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):1-4. PubMed ID: 16616280
[TBL] [Abstract][Full Text] [Related]
37. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
[TBL] [Abstract][Full Text] [Related]
38. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
39. The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.
Magné N; Chargari C; Castadot P; Ghalibafian M; Soria JC; Haie-Meder C; Bourhis J; Deutsch E
Eur J Cancer; 2008 Oct; 44(15):2133-43. PubMed ID: 18692389
[TBL] [Abstract][Full Text] [Related]
40. Multidisciplinary team-working indicators of good practice in the clinical management of EGFR-inhibitor dermatologic toxicities.
Manganoni AM; Farisoglio C; Ferrari V; Zaniboni A; Beretta G; Meriggi F; Calzavara-Pinton P
Ann Surg Oncol; 2009 Jan; 16(1):224-5. PubMed ID: 18989724
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]